William Blair Brokers Reduce Earnings Estimates for Avantor

Avantor, Inc. (NYSE:AVTR) – Analysts at William Blair dropped their Q3 2025 EPS estimates for shares of Avantor in a report issued on Friday, February 7th. William Blair analyst M. Larew now anticipates that the company will post earnings of $0.28 per share for the quarter, down from their previous estimate of $0.29. The consensus estimate for Avantor’s current full-year earnings is $0.98 per share. William Blair also issued estimates for Avantor’s FY2025 earnings at $1.11 EPS.

Avantor (NYSE:AVTR) last released its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same period in the prior year, the company earned $0.22 EPS.

Other equities analysts have also recently issued reports about the stock. Stifel Nicolaus decreased their target price on shares of Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Monday. UBS Group reissued a “neutral” rating and issued a $25.00 price objective (down previously from $29.00) on shares of Avantor in a research report on Friday, January 17th. Royal Bank of Canada dropped their target price on shares of Avantor from $33.00 to $31.00 and set an “outperform” rating on the stock in a report on Monday. Barclays reduced their price target on Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Monday. Finally, Wells Fargo & Company dropped their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.15.

Avantor Stock Down 0.9 %

NYSE:AVTR opened at $19.00 on Monday. Avantor has a twelve month low of $18.49 and a twelve month high of $28.00. The firm has a market capitalization of $12.93 billion, a price-to-earnings ratio of 41.30, a price-to-earnings-growth ratio of 3.87 and a beta of 1.28. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The stock’s 50 day moving average price is $21.73 and its two-hundred day moving average price is $23.47.

Hedge Funds Weigh In On Avantor

Institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp increased its stake in Avantor by 58.0% during the 3rd quarter. State Street Corp now owns 22,368,244 shares of the company’s stock worth $578,666,000 after acquiring an additional 8,206,695 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Avantor by 653.0% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock worth $159,740,000 after purchasing an additional 5,354,678 shares in the last quarter. FMR LLC increased its position in shares of Avantor by 557.2% in the third quarter. FMR LLC now owns 4,675,283 shares of the company’s stock worth $120,950,000 after purchasing an additional 3,963,912 shares during the period. Janus Henderson Group PLC raised its stake in Avantor by 18.2% in the third quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock valued at $457,710,000 after purchasing an additional 2,719,615 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Avantor during the fourth quarter worth about $33,091,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.